Followers | 128 |
Posts | 2150 |
Boards Moderated | 1 |
Alias Born | 12/27/2007 |
Wednesday, July 10, 2019 12:49:07 PM
this new pipeline update is from last month
https://ir.etonpharma.com/news-releases/news-release-details/eton-pharmaceuticals-announces-licensing-lamotrigine-new-drug
EM-100. EM-100, Eton’s preservative-free ophthalmic solution for allergic conjunctivitis has been assigned a target action date of July 11, 2019. Bausch Health will be responsible for all remaining regulatory and commercial activities surrounding the product. Eton is entitled to a milestone payment upon product launch and a royalty on commercial sales.
this is from early may
https://ir.etonpharma.com/news-releases/news-release-details/eton-pharmaceuticals-reports-first-quarter-2019-financial
EM-100. EM-100 is Eton’s preservative-free ophthalmic solution for the treatment of allergic conjunctivitis. The product is currently under review with the FDA and has been assigned a target action date of May 2019 or July 2019 depending on whether the FDA chooses to inspect EM-100’s manufacturing site. Bausch Health is responsible for all commercialization activities for the product.
Recent ETON News
- Eton Pharmaceuticals to Participate at the H.C. Wainwright 26th Annual Global Investment Conference • GlobeNewswire Inc. • 08/22/2024 08:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 08:25:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 08:21:24 PM
- Eton Pharmaceuticals Reports Second Quarter 2024 Financial Results • GlobeNewswire Inc. • 08/08/2024 08:01:00 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 08/02/2024 08:16:27 PM
- Eton Pharmaceuticals to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024 • GlobeNewswire Inc. • 07/30/2024 09:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/15/2024 08:16:01 PM
- Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-400 (Hydrocortisone Oral Solution) • GlobeNewswire Inc. • 07/15/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/11/2024 08:18:06 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:25:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:17:24 PM
- Eton Pharmaceuticals Reports First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/09/2024 08:01:00 PM
- Eton Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference • GlobeNewswire Inc. • 05/01/2024 08:05:00 PM
- Eton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution) • GlobeNewswire Inc. • 04/30/2024 11:00:00 AM
- Eton Pharmaceuticals to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024 • GlobeNewswire Inc. • 04/29/2024 08:30:00 PM
- Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria • GlobeNewswire Inc. • 03/22/2024 06:00:00 AM
- Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/14/2024 08:01:00 PM
- Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 14, 2024 • GlobeNewswire Inc. • 02/29/2024 09:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/21/2024 11:55:25 AM
- Eton Pharmaceuticals Awarded U.S. Patent for Proprietary Hydrocortisone Oral Liquid Formulation • GlobeNewswire Inc. • 02/21/2024 11:50:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:21:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:19:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:17:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 11:55:44 AM
- Eton Pharmaceuticals Announces Commercial Availability of Ultra-Rare Disease Product Nitisinone Capsules • GlobeNewswire Inc. • 02/02/2024 11:50:00 AM
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition • PFE • Oct 2, 2024 9:00 AM
Unitronix Corp Unveils Cryptocurrency Investment Portfolio Strategy • UTRX • Oct 2, 2024 8:40 AM
Integrated Ventures, Inc Reports Total 2024 Revenues Of $5,863,935 vs $3,862,849 for 2023. • INTV • Oct 1, 2024 9:00 AM
Nightfood Signs Letter of Intent to Acquire Los Angeles Cooking School, Integrating Automation and Robotics with World-Class Culinary Training • NGTF • Oct 1, 2024 8:30 AM
ZenaTech, Inc. (NASDAQ: ZENA) To Commence Trading Today • COOP • Oct 1, 2024 7:00 AM
Element79 Gold Corp secures loi for launching tailings reprocessing business in Arequipa, Peru • ELMGF • Oct 1, 2024 6:38 AM